REPLIGEN CORP acquisition history.

Acquisition of the bioprocessing business of Novozymes Biopharma Sweden AB, a supplier of cell-culture growth factors and other products used in the manufacture of biologic drugs. Repligen called it a transformative deal that elevated the company to a world-leading supplier of products for manufacturing biologic drugs and accelerated its path to sustainable profitability. ~$22.7 million (EUR 17 million) cash + up to EUR 4 million (~$5.6M) milestones.

Acquisition of Refine Technology's business, centered on the market-leading ATF (Alternating Tangential Flow) System used by biopharmaceutical manufacturers for perfusion cell culture. Repligen called it a significant step toward building a best-in-class bioprocessing company. ~$24.5 million upfront ($20.5M cash + Repligen stock) plus up to $8.75M milestones and a capped royalty up to $2.15M.

Acquisition of Atoll GmbH & Co. KG, maker of the MediaScout family of pre-packed chromatography products, broadening Repligen's portfolio and expanding its customer base, particularly complementing the OPUS pre-packed disposable chromatography column line. ~$22.5 million total upfront ($9.1M cash + Repligen stock) plus a potential EUR 1.0M payment.

Acquisition of TangenX Technology Corporation, adding innovative single-use, flat-sheet tangential flow filtration (TFF) cassettes (the SIUS line) to Repligen's filtration portfolio. EUR 37.0 million (~USD 39.0 million), all cash.

Acquisition of Spectrum, Inc., a maker of hollow-fiber (HF) filtration products and KrosFlo TFF systems plus the Spectra/Por dialysis line, in a transaction Repligen called pivotal. Spectrum recorded revenue of $40.2 million in 2016. The deal substantially expanded Repligen's filtration franchise and global commercial footprint. ~$359 million ($120M cash + ~$239M in Repligen stock).

Acquisition of privately held C Technologies, Inc., maker of the SoloVPE and FlowVPE Slope Spectroscopy systems for real-time protein concentration measurement, establishing Repligen's Process Analytics franchise. Projected to contribute ~$16-$17 million in revenue. ~$240 million ($192M cash + $48M in Repligen stock).

Acquisition of Engineered Molding Technology LLC, a manufacturer of single-use silicone assemblies and components used in the manufacture of biologic drugs. EMT expands Repligen's ProConnex flow-path line and streamlines its ATF supply chain. Effective July 11, 2021, EMT was absorbed into Repligen via short-form merger.

Acquisition of Non-Metallic Solutions, Inc., a manufacturer of fabricated plastics, custom containers and related assemblies and components used in manufacturing biologic drugs. NMS's fluid-management products complement and expand Repligen's single-use flow paths and durable-plastics portfolio.

Acquisition of ARTeSYN Biosolutions, a maker of gold-standard single-use downstream bioprocessing systems including automated chromatography and filtration systems with unique single-use flow-path designs. The deal advanced Repligen's Systems strategy in Filtration and Chromatography, complementing TangenX flat-sheet cassettes and OPUS pre-packed columns. ARTeSYN was projected to generate ~$30 million in revenue. ~$200 million (~$130M cash + ~$70M in Repligen stock).

Acquisition of Polymem S.A., a French manufacturer of hollow-fiber membranes, membrane modules and systems for industrial and bioprocessing applications. Polymem expanded Repligen's HF membrane and module production capacity, added core R&D and engineering expertise in HF technology, and established a Europe-based HF manufacturing center of excellence complementing the Spectrum HF / KrosFlo product line. ~$47 million, all cash.

Acquisition of privately held Avitide, Inc., a market leader in affinity ligand discovery and development, moving Repligen into affinity resin solutions for gene therapy and other emerging modalities. The deal strengthened Repligen's Proteins business and complemented its established partnership with Navigo GmbH. Avitide was expected to contribute ~$10 million in revenue in 2022. ~$150 million ($75M cash + $75M in Repligen stock).

Acquisition of Newton T&M Corp (NTM), the parent of BioFlex Solutions, LLC, including BioFlex's commercialization arm and NTM's manufacturing operations. Both companies, headquartered in Newton, New Jersey, manufacture and commercialize single-use fluid-management products, expanding Repligen's single-use flow-path and assembly capabilities. ~$31.6 million total consideration.

Acquisition of all outstanding equity interests in FlexBiosys, Inc., a custom designer and manufacturer of single-use bioprocessing products, strengthening Repligen's fluid-management portfolio. Earnout periods run from Jan 1, 2023 through Dec 31, 2024. ~$41.0 million total ($29.0M cash + Repligen stock, plus earnouts).

Acquisition of privately held Metenova AB of Molndal, Sweden, adding market-leading magnetic mixing and drive-train technology for upstream and downstream bioprocess applications, including the single-use MixOne platform. Metenova was projected to generate $24-$25 million of revenue in fiscal 2023. ~$172.6 million total ($164.5M cash + Repligen stock, plus ~$10M earnout).

Acquisition of Tantti Laboratory Inc. of Taoyuan City, Taiwan, developer of a portfolio of macroporous chromatography beads (including Dulocore base bead technology) to optimize purification of new modalities such as viral vectors, viruses and nucleic acids. The technology underpins Repligen's HiPer base beads and AVIPure resin extensions. Tantti contributed $78.1 million of total assets and no revenue as of Dec 31, 2024. ~$54.8 million cash (net of cash acquired), plus up to $54.5 million earnout.

Acquisition of 908 Devices Inc.'s desktop portfolio of four bioprocessing process analytical technology (PAT) devices, together with related facilities, employees, equipment and lease obligations in North Carolina and Braunschweig, Germany. The deal added upstream PAT solutions, complementing the downstream PAT capability gained from C Technologies in 2019, and was rebranded under the PATsmart line in 2025. ~$70.3 million total consideration.